loading page

VERY EARLY DIAGNOSIS AND MANAGEMENT OF CONGENITAL ERYTHROPOIETIC PORPHYRIA AT BIRTH
  • +3
  • Marie-Pier Desjardins,
  • Lamia Naccache,
  • Audrey Hébert,
  • Isabelle Auger,
  • Pierre Teira,
  • Marie-Claude Pelland-Marcotte
Marie-Pier Desjardins
CHU de Québec-Université Laval

Corresponding Author:mariepier.desjardins.5@gmail.com

Author Profile
Lamia Naccache
Centre hospitalier universitaire de Québec-Université Laval
Author Profile
Audrey Hébert
CHU de Québec-Université Laval
Author Profile
Isabelle Auger
CHU de Québec-Université Laval
Author Profile
Pierre Teira
Centre Hospitalier Universitaire Sainte-Justine
Author Profile
Marie-Claude Pelland-Marcotte
Centre hospitalier universitaire de Québec-Université Laval
Author Profile

Abstract

Congenital erythropoietic porphyria (CEP) is caused by a defect in the heme biosynthesis pathway of the enzyme uroporphyrinogen III synthase (UROS) leading to an accumulation of non-physiological porphyrins. The exposure of accumulated porphyrins to sunlight causes severe photosensitivity, chronic intravascular hemolysis and, eventually, irreversible mutilating deformities. Several supportive therapies such as strict sun avoidance, physical sunblocks, red blood cells transfusion, hydroxyurea and splenectomy are commonly used in the management of CEP. Currently, the only available curative treatment of CEP is HSCT. We present a child with a very early diagnosis of CEP, who became the youngest successful HSCT for CEP.